Four of the 15 responses occurred in patients with estrogen receptor-negative, progesterone receptor-negative, and HER2-negative (triple-negative) breast cancer, suggesting such a regimen may be effective for patients with this treatment-resistant subtype [91]. This evidence concerns the gene ERBB2 and breast carcinoma.